Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03733639
Other study ID # Tisseel
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date July 21, 2020
Est. completion date July 1, 2022

Study information

Verified date July 2020
Source Germans Trias i Pujol Hospital
Contact Elisenda Garsot
Phone 0034934978803
Email egarsot@yahoo.es
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background:

The dehiscence of esophagojejunal anastomoses is one of the most serious complications after total gastrectomy in patients with gastric cancer. Any method of avoiding this problem will affect not only the postoperative course but also the prognostic of disease.

Methods:

This is a prospective, randomized and multicenter trial, within the Spanish EURECCA Esophagogastric Cancer Group, to investigate the efficacy of Tisseel® in reducing the rate of esophagojejunal anastomosis leakage in patients with gastric cancer. The rate of anastomosis leak will be measured with clinical, radiological and analytic parameters.

Objective:

Analyze the efficacy of Tisseel® as a reinforcement in reducing the rate of anastomotic esophagojejunal anastomoses.


Description:

Introduction The dehiscence of the esophagojejunal anastomosis is one of the most serious complications after a total gastrectomy not only in the short term but it has been shown to be an independent risk factor for survival. The rate of esophagojejunal anastomosis leakage after cancer gastrectomies is described to be between 1-12.3%.

Any method to prevent this complication would be of vital importance to improve the evolution of these patients. Likewise, when the dehiscence has been established, early detection could contribute to an early intervention, avoiding more serious consequences and, therefore, improving the short and long term prognosis.

Little progress has been made during recent decades in the prevention of anastomotic leakage in high-risk digestive tract anastomosis. Some authors have tried the use of new methods of suture, reinforcements or patches in the anastomosis. Fibrin adhesives were introduced more than 30 years ago, in order to favor hemostasis and tissue adhesion. Numerous studies have demonstrated their effectiveness in reducing surgical bleeding in cardiovascular surgery but its role as a sealant in gastrointestinal anastomosis is more debated. There have been some experimental studies that have shown a possible protective effect of this material in enteric anastomoses. With the evolution of bariatric surgery and with the high volume of surgeries handled, several studies have been published that assess the effect of fibrin sealants on gastrojejunal anastomoses. In esophagogastric surgery, the number of published studies is reduced and there are only 2 studies that assess the effect of fibrin sealants on esophagojejunal anastomosis. The results of these studies seem to indicate that the application of fibrin sealants in this anastomosis could have a favorable effect in reducing the number of anastomotic dehiscences.

There are different definitions for the concept of "anastomotic dehiscence". The dehiscence of the esophago-jejunal anastomotic can be defined as any clinical and / or radiological evidence of dehiscence of the anastomosis. Although early diagnosis is key to avoiding major consequences, in clinical practice, the diagnosis of anastomotic dehiscence is often delayed. Direct observation of the debit of surgical drainage, fever or persistent ileus or clear symptoms of peritonitis are indirect signs that make us suspect a possible anastomotic dehiscence. The possibility of having a parameter that allows us to diagnose early a problem in the suture would allow us to act earlier and, therefore, improve the prognosis of these patients in the short and long term.

In colorectal surgery, serological parameters such as procalcitonin or C-reactive protein have been studied as early predictors of anastomotic dehiscence. In esophagogastric surgery, publications are scarce and all of them analyze results in esophagogastric anastomoses.

Furthermore, the determination of amylases in drainage has also been used for the detection of postoperative fistula. It is a simple and low cost method and is a parameter widely used in pancreatic surgery for the detection and evolutionary control of pancreatic fistulas. It has also been shown to be useful in esophageal surgery and in bariatric surgery. However, in gastric cancer it has only been used for the diagnosis of pancreatic fistula as a complication in total gastrectomies with associated splenectomy.

Finally, the use of radiology with oral contrast routinely in the postoperative period of esophagogastric surgery has been shown to have a low sensitivity for the early detection of anastomotic dehiscence. CT with oral contrast seems to have greater sensitivity and positive predictive value in esophageal surgery for this purpose, but the need to perform a postoperative test to evaluate the anastomosis without clinical evidence of dehiscence is unclear.

For all these reasons, we believe that a multicenter randomized study will contribute to improve the clinical results of esophagogastric surgery and the knowledge of the diagnosis of complications, by studying the efficacy of Tisseel® in reducing the rate of anastomotic leakage, but also analyzing the role of drain amylases, serum CRP (C-reactive protein), procalcitonin and white blood cell levels in the early detection and prediction of anastomotic leak, and the role of CT with oral contrast as a routine assessment of anastomotic integrity.

Objective Analyze the efficacy of Tisseel® in reducing the rate of anastomotic leakage diagnosed in the postoperative period using clinical and / or radiological parameters.

Methods This is a prospective, randomized and multicenter trial, within the Spanish EURECCA Esophagogastric Cancer Project, to investigate the efficacy of Tisseel® in reducing the rate of esophagojejunal anastomosis leakage in patients with gastric cancer.

Participation study will be offered to all centers that are currently part of the Spanish EURECCA Esophagogastric Cancer Group. Those hospitals that show their desire to participate must sign the Letter of Commitment. In the same way, the study must sign off by European Medicine Agency and Spanish Agency of Medicines.

Once the patient is included in the study the surgeon performs a total gastrectomy as usual procedure. Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). Surgeon dispenses Tisseel® all over the anastomosis following data sheet if applicable. The rest of the surgical procedure is as usual. In the postoperative period the investigator collects the data commented in following sections.

The evidence of an anastomotic leak will be tested with analytical and radiological parameters:

1. Blood samples will be taken from patients at:

- Immediate preoperative (blood count, procalcitonin and C-reactive protein)

- Days 1, 3, 5 and 7 postoperative (blood count, procalcitonin and C-reactive protein).

2. A sample of surgical drainage will be collected for the determination of amylases on days: 1,3,5, and 7 postoperative or until drainage is withdrawn.

3. An abdominal CT with oral contrast will be performed within the first 5 postoperative days. The date and the result will be collected.


Recruitment information / eligibility

Status Recruiting
Enrollment 146
Est. completion date July 1, 2022
Est. primary completion date July 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients over 18 years diagnosed with gastric adenocarcinoma and scheduled for a total gastrectomy with curative intent in EURECCA Esophagogastric Cancer Group who agree to participate in the study and sign the informed consent

Exclusion Criteria:

- Patients with non-epithelial neoplasms, with metastases, not resected or undergoing palliative resections. Patients who do not sign informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tisseel
Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.
Device:
No Tisseel
No reinforcement of esophagojejunal anastomoses after total gastrectomy

Locations

Country Name City State
Spain Elisenda Garsot Savall Badalona Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Germans Trias i Pujol Hospital

Country where clinical trial is conducted

Spain, 

References & Publications (31)

Aurello P, Magistri P, D'Angelo F, Valabrega S, Sirimarco D, Tierno SM, Nava AK, Ramacciato G. Treatment of esophagojejunal anastomosis leakage: a systematic review from the last two decades. Am Surg. 2015 May;81(5):450-3. Review. — View Citation

Baker EH, Hill JS, Reames MK, Symanowski J, Hurley SC, Salo JC. Drain amylase aids detection of anastomotic leak after esophagectomy. J Gastrointest Oncol. 2016 Apr;7(2):181-8. doi: 10.3978/j.issn.2078-6891.2015.074. — View Citation

Berkelmans GH, Kouwenhoven EA, Smeets BJ, Weijs TJ, Silva Corten LC, van Det MJ, Nieuwenhuijzen GA, Luyer MD. Diagnostic value of drain amylase for detecting intrathoracic leakage after esophagectomy. World J Gastroenterol. 2015 Aug 14;21(30):9118-25. doi: 10.3748/wjg.v21.i30.9118. — View Citation

Bonanomi G, Prince JM, McSteen F, Schauer PR, Hamad GG. Sealing effect of fibrin glue on the healing of gastrointestinal anastomoses: implications for the endoscopic treatment of leaks. Surg Endosc. 2004 Nov;18(11):1620-4. Epub 2004 Oct 11. — View Citation

Borst HG, Haverich A, Walterbusch G, Maatz W. Fibrin adhesive: an important hemostatic adjunct in cardiovascular operations. J Thorac Cardiovasc Surg. 1982 Oct;84(4):548-53. — View Citation

Bruce J, Krukowski ZH, Al-Khairy G, Russell EM, Park KG. Systematic review of the definition and measurement of anastomotic leak after gastrointestinal surgery. Br J Surg. 2001 Sep;88(9):1157-68. Review. — View Citation

Cools-Lartigue J, Andalib A, Abo-Alsaud A, Gowing S, Nguyen M, Mulder D, Ferri L. Routine contrast esophagram has minimal impact on the postoperative management of patients undergoing esophagectomy for esophageal cancer. Ann Surg Oncol. 2014 Aug;21(8):2573-9. doi: 10.1245/s10434-014-3654-1. Epub 2014 Mar 28. — View Citation

De Stefano A, Bettarini F, Di Mare G, Neri A. [Enteric anastomosis and Tachosil®]. Minerva Chir. 2011 Jun;66(3):183-8. Italian. — View Citation

Dutta S, Fullarton GM, Forshaw MJ, Horgan PG, McMillan DC. Persistent elevation of C-reactive protein following esophagogastric cancer resection as a predictor of postoperative surgical site infectious complications. World J Surg. 2011 May;35(5):1017-25. doi: 10.1007/s00268-011-1002-1. — View Citation

Fernandez Fernandez L, Tejero E, Tieso A. Randomized trial of fibrin glue to seal mechanical oesophagojejunal anastomosis. Br J Surg. 1996 Jan;83(1):40-1. — View Citation

Garcia-Granero A, Frasson M, Flor-Lorente B, Blanco F, Puga R, Carratalá A, Garcia-Granero E. Procalcitonin and C-reactive protein as early predictors of anastomotic leak in colorectal surgery: a prospective observational study. Dis Colon Rectum. 2013 Apr;56(4):475-83. doi: 10.1097/DCR.0b013e31826ce825. — View Citation

Giaccaglia V, Salvi PF, Antonelli MS, Nigri G, Pirozzi F, Casagranda B, Giacca M, Corcione F, de Manzini N, Balducci G, Ramacciato G. Procalcitonin Reveals Early Dehiscence in Colorectal Surgery: The PREDICS Study. Ann Surg. 2016 May;263(5):967-72. doi: 10.1097/SLA.0000000000001365. — View Citation

Hayati F, Mohd Azman ZA, Nasuruddin DN, Mazlan L, Zakaria AD, Sagap I. Serum Procalcitonin Predicts Anastomotic Leaks in Colorectal Surgery. Asian Pac J Cancer Prev. 2017 Jul 27;18(7):1821-1825. — View Citation

Hoeboer SH, Groeneveld AB, Engels N, van Genderen M, Wijnhoven BP, van Bommel J. Rising C-reactive protein and procalcitonin levels precede early complications after esophagectomy. J Gastrointest Surg. 2015 Apr;19(4):613-24. doi: 10.1007/s11605-015-2745-z. Epub 2015 Feb 7. — View Citation

Jones CM, Clarke B, Heah R, Griffiths EA. Should routine assessment of anastomotic integrity be undertaken using radiological contrast swallow after oesophagectomy with intra-thoracic anastomosis? Best evidence topic (BET). Int J Surg. 2015 Aug;20:158-62. doi: 10.1016/j.ijsu.2015.06.076. Epub 2015 Jul 10. Review. — View Citation

Kjaergard HK, Fairbrother JE. Controlled clinical studies of fibrin sealant in cardiothoracic surgery--a review. Eur J Cardiothorac Surg. 1996;10(9):727-33. Review. — View Citation

Lago Oliver J, Arjona Medina I, Martín García-Almenta E, Martín Gil J, Sanz Sánchez M, Pérez Díaz MD, Alonso Poza A, Turégano Fuentes F, Torres García A. [Use of fibrin based biological adhesives in the prevention of anastomotic leaks in the high risk digestive tract: preliminary results of the multicentre, prospective, randomised, controlled, and simple blind phase IV clinical trial: Protissucol001]. Cir Esp. 2012 Dec;90(10):647-55. doi: 10.1016/j.ciresp.2012.05.007. Epub 2012 Jun 27. Spanish. — View Citation

Maher JW, Bakhos W, Nahmias N, Wolfe LG, Meador JG, Baugh N, Kellum JM. Drain amylase levels are an adjunct in detection of gastrojejunostomy leaks after Roux-en-Y gastric bypass. J Am Coll Surg. 2009 May;208(5):881-4; discussion 885-6. doi: 10.1016/j.jamcollsurg.2008.12.022. Epub 2009 Mar 26. — View Citation

Matthew TL, Spotnitz WD, Kron IL, Daniel TM, Tribble CG, Nolan SP. Four years' experience with fibrin sealant in thoracic and cardiovascular surgery. Ann Thorac Surg. 1990 Jul;50(1):40-3; discussion 43-4. — View Citation

Migita K, Takayama T, Matsumoto S, Wakatsuki K, Enomoto K, Tanaka T, Ito M, Nakajima Y. Risk factors for esophagojejunal anastomotic leakage after elective gastrectomy for gastric cancer. J Gastrointest Surg. 2012 Sep;16(9):1659-65. doi: 10.1007/s11605-012-1932-4. Epub 2012 Jun 12. — View Citation

Noble F, Curtis N, Harris S, Kelly JJ, Bailey IS, Byrne JP, Underwood TJ; South Coast Cancer Collaboration–Oesophago-Gastric (SC-OG). Risk assessment using a novel score to predict anastomotic leak and major complications after oesophageal resection. J Gastrointest Surg. 2012 Jun;16(6):1083-95. doi: 10.1007/s11605-012-1867-9. Epub 2012 Mar 15. — View Citation

Perry Y, Towe CW, Kwong J, Ho VP, Linden PA. Serial Drain Amylase Can Accurately Detect Anastomotic Leak After Esophagectomy and May Facilitate Early Discharge. Ann Thorac Surg. 2015 Dec;100(6):2041-6; discussion 2046-7. doi: 10.1016/j.athoracsur.2015.05.092. Epub 2015 Aug 25. — View Citation

Reid-Lombardo KM, Farnell MB, Crippa S, Barnett M, Maupin G, Bassi C, Traverso LW; Pancreatic Anastomotic Leak Study Group. Pancreatic anastomotic leakage after pancreaticoduodenectomy in 1,507 patients: a report from the Pancreatic Anastomotic Leak Study Group. J Gastrointest Surg. 2007 Nov;11(11):1451-8; discussion 1459. Epub 2007 Aug 21. — View Citation

Saldaña-Cortés JA, Larios-Arceo F, Prieto-Díaz-Chávez E, De Buen EP, González-Mercado S, Alvarez-Villaseñor AS, Prieto-Aldape MR, Fuentes-Orozco C, González-Ojeda A. Role of fibrin glue in the prevention of cervical leakage and strictures after esophageal reconstruction of caustic injury. World J Surg. 2009 May;33(5):986-93. doi: 10.1007/s00268-009-9949-x. — View Citation

Sano T, Sasako M, Katai H, Maruyama K. Amylase concentration of drainage fluid after total gastrectomy. Br J Surg. 1997 Sep;84(9):1310-2. — View Citation

Silecchia G, Boru CE, Mouiel J, Rossi M, Anselmino M, Morino M, Toppino M, Gaspari A, Gentileschi P, Tacchino R, Basso N. The use of fibrin sealant to prevent major complications following laparoscopic gastric bypass: results of a multicenter, randomized trial. Surg Endosc. 2008 Nov;22(11):2492-7. doi: 10.1007/s00464-008-9885-0. Epub 2008 Mar 26. — View Citation

Strauss C, Mal F, Perniceni T, Bouzar N, Lenoir S, Gayet B, Palau R. Computed tomography versus water-soluble contrast swallow in the detection of intrathoracic anastomotic leak complicating esophagogastrectomy (Ivor Lewis): a prospective study in 97 patients. Ann Surg. 2010 Apr;251(4):647-51. doi: 10.1097/SLA.0b013e3181c1aeb8. — View Citation

Struecker B, Chopra S, Heilmann AC, Spenke J, Denecke C, Sauer IM, Bahra M, Pratschke J, Andreou A, Biebl M. Routine Radiologic Contrast Agent Examination After Gastrectomy for Gastric Cancer Is Not Useful. J Gastrointest Surg. 2017 May;21(5):801-806. doi: 10.1007/s11605-017-3384-3. Epub 2017 Feb 15. — View Citation

Upadhyaya VD, Gopal SC, Gangopadhyaya AN, Gupta DK, Sharma S, Upadyaya A, Kumar V, Pandey A. Role of fibrin glue as a sealant to esophageal anastomosis in cases of congenital esophageal atresia with tracheoesophageal fistula. World J Surg. 2007 Dec;31(12):2412-5. — View Citation

Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, Song KY. Negative impact of leakage on survival of patients undergoing curative resection for advanced gastric cancer. J Surg Oncol. 2011 Dec;104(7):734-40. doi: 10.1002/jso.22045. Epub 2011 Jul 25. — View Citation

Yuan Y, Zeng X, Hu Y, Xie T, Zhao Y. Omentoplasty for esophagogastrostomy after esophagectomy. Cochrane Database Syst Rev. 2012 Nov 14;11:CD008446. doi: 10.1002/14651858.CD008446.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;10:CD008446. — View Citation

* Note: There are 31 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of esophagojejunal anastomotic leak in immediate postoperative period Clinical or radiological (see anex 1: Score Goense) evidence of esophagojejunal anastomotic leak. 7 days
Secondary Amylases level in drainage Amylase level (mg/L) in drainage days 1,3,5,7 postoperatively
Secondary CRP (C-reactive protein) in blood C-reactive protein in blood (mg/L) days 1,3,5,7 postoperatively
Secondary Procalcitonin in blood Procalcitonin in blood (mg/L) days 1,3,5,7 postoperatively
Secondary White cell levels in blood White cell levels in blood (x109/L) days 1,3,5,7 postoperatively
Secondary Results of Computed Tomography with oral contrast. The results will be expressed based on Goense Score
Based on Score Goense (Anastomotic Leakage Prediction Score). The investigator will collect the presence of:
Yes No Normal Fluid collection Air cavity Fistula Wall discontinuity Empiema
Goense L, Stassen PMC, Wessels FJ, van Rossum PSN, Ruurdal JP, van Leeuwen MS, van Hillegersberg R. Diagnostic performance of a CT-based scoring system for diagnosis of anastomotic leakage after esophagectomy: comparison with subjective CT assessment. Eur Radiol 2017; 27:4426-34
between 3th and 5th postoperative day
Secondary Type of esophagojejunal anastomoses performed The type of esophagojejunal anastomoses performed can be:
mechanical (circular)
mechanical (lineal)
manual
day of intervention
Secondary Postoperative complications Postoperative complications (Clavien-Dindo score):
Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions
Grade II Requiring pharmacological treatment with drugs other than such allowed for grade I complications.
Grade III Requiring surgical, endoscopic or radiological intervention
IIIa Intervention not under general anesthesia
IIIb Intervention under general anesthesia
Grade IV Life-threatening complication requiring IC/ICU-management
IVa single organ dysfunction (including dialysis)
IVb multiorgandysfunction
Grade V Death of a patient
30 days after surgery
Secondary 90-day mortality Mortality at 90 days after surgery 90 days after surgery
Secondary Need for urgent surgical re-intervention Reintervention after surgery:
Yes/Not
30 days after surgery
Secondary Hospital stay Number of days of hospital stay 30 days after surgery
Secondary Readmission Readmission within 30 days after discharge:
Yes/Not
30 days after discharge
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2